User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 36.00 35.00 37.00 36.00 36.00 36.00 6,003 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -21.9 -9.8 - 126

Advanced Oncotherapy PLC Exercise of Warrants and Issue of Equity

11/03/2021 7:00am

UK Regulatory (RNS & others)


Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart


From Mar 2021 to May 2021

Click Here for more Advanced Oncotherapy Charts.

TIDMAVO

RNS Number : 8754R

Advanced Oncotherapy PLC

11 March 2021

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Exercise of Warrants and Issue of Equity

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has received a warrant exercise notice in respect of 361,111 new ordinary shares of 25 pence in the Company ("New Ordinary Shares"), with an exercise price of 36 pence per share.

Once issued, the New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Application has been made for the 361,111 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or around 16 March 2021.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 349,401,725 Ordinary Shares of 25 pence each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 349,401,725 .

The above figure of 349,401,725 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- ENDS -

 
 Advanced Oncotherapy plc                                                        www.avoplc.com 
 Dr Michael Sinclair, Executive Chairman                              Tel: +44 (0) 20 3617 8728 
 Nicolas Serandour, CEO 
 
 Allenby Capital Limited (Nomad and Joint Broker) 
 Nick Athanas / Liz Kirchner (Corporate Finance)                      Tel: +44 (0) 20 3328 5656 
  Amrit Nahal / Matt Butlin (Sales & Corporate Broking) 
 
 SI Capital Ltd (Joint Broker) 
 Nick Emerson                                                         Tel: +44 (0) 1483 413 500 
 Jon Levinson                                                         Tel: +44 (0) 20 3871 4066 
 
 FTI Consulting (Financial PR & IR)                       advancedoncotherapy@fticonsulting.com 
 Simon Conway / Rob Winder                                            Tel: +44 (0) 20 3727 1000 
 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEJMMTTMTMBTAB

(END) Dow Jones Newswires

March 11, 2021 02:00 ET (07:00 GMT)

1 Year Advanced Oncotherapy Chart

1 Year Advanced Oncotherapy Chart

1 Month Advanced Oncotherapy Chart

1 Month Advanced Oncotherapy Chart
ADVFN Advertorial
Your Recent History
LSE
AVO
Advanced O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210508 23:28:29